Efficacy and tolerability of orally administered tramadol/dexketoprofen fixed-dose combination compared to diclofenac/thiocolchicoside in acute low back pain: experience from an Italian, single-centre, observational study

Meloncelli, Stefano; Divizia, Marco; Germani, Giorgio

doi:10.1080/03007995.2020.1814228

Cited by 12 publications

(19 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dexketoprofen/tramadol 75/25 mg group also exhibited a significantly greater reduction in neuropathic pain. Both treatments were similarly well tolerated [36].…”

Section: Agentmentioning

confidence: 83%

“…Examples of fixed-dose combination products include acetaminophen/oxycodone, dexketoprofen/tramadol, acetaminophen/hydrocodone, and diclofenac/thiocolchicoside. A study of 82 acute LBP outpatients compared the efficacy and tolerability of dexketoprofen/tramadol 75/25 mg to diclofenac/tiocolchisoide 75/4 mg [36]. In this study, patients had acute LBP caused by a herniated disc rated above four on a zero-ten pain scale.…”

Section: Agentmentioning

confidence: 99%

See 1 more Smart Citation

What Is New in the Clinical Management of Low Back Pain: A Narrative Review

Orrillo¹,

Neira²,

Piedimonte³

et al. 2022

Cureus

View full text Add to dashboard Cite

Low back pain (LBP) is a prevalent condition associated with disability. Treating patients with LBP becomes further complicated by the potential presence of underlying conditions, such as cancer or traumatic injury, or biopsychosocial aspects. LBP usually has a neuropathic component that must be assessed and treated appropriately. Pharmacological management of LBP requires a thorough knowledge of the available agents and the mechanisms of the LBP. Although there are effective pharmacological treatments for LBP, it is important to consider safety issues. Fixed-dose combination products may be helpful, as they can reduce opioid consumption without sacrificing analgesic benefits. Neuromodulation is an important and sometimes overlooked treatment option for LBP and may be appropriate for chronic LBP requiring long-term treatment. Imaging studies support neuroplastic changes in the brain as a result of neuromodulation. Interventional approaches to chronic LBP are numerous and must be appropriately selected based on the individual patient. Evidence in support of epidural injections for LBP is strong for short-term pain control but moderate to limited for long-term relief. Rehabilitation for LBP can be an important element of long-term care, and new forms of rehabilitation programs are being developed using telemedicine. A variety of new and established treatments are available for patients with LBP, and clinicians and patients may benefit from emerging new treatment modalities.

show abstract

“…The dexketoprofen/tramadol 75/25 mg group also exhibited a significantly greater reduction in neuropathic pain. Both treatments were similarly well tolerated [36].…”

Section: Agentmentioning

confidence: 83%

Section: Agentmentioning

confidence: 99%

What Is New in the Clinical Management of Low Back Pain: A Narrative Review

Orrillo¹,

Neira²,

Piedimonte³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…The main strengths of the DANTE study are the large sample size (larger than previous COX inhibitors and COX inhibitor/opioid combination study cohorts enrolling LBP patients) [33,34,44,45,50], the heterogeneity of the study population, resembling real-life conditions, the use of multiple analgesic and function assessments, and the comprehensive evaluation of patients' perspective, often neglected in previous clinical trials [28,33,34,50]. One limitation of the study is the lack of a treatment arm receiving a COX inhibitor/opioid combination; nevertheless, in a previous acute moderate-tosevere pain model, TRAM/DKP 75/25 mg demonstrated to be more effective than paracetamol/TRAM in the largest study so far performed in acute patients undergoing impacted third molar extraction [42].…”

Section: Discussionmentioning

confidence: 99%

DANTE Study: The First Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Arm Group Study Evaluating the Analgesic Efficacy and Safety of Dexketoprofen TrometAmol aNd Tramadol Hydrochloride Oral FixEd Dose Combination on Moderate to Severe Acute Pain in Patients with Acute Low Back Pain—Rationale and Design

Varrassi

Hanna²,

Coaccioli

et al. 2022

Pain Ther

View full text Add to dashboard Cite

Introduction: Despite a wide range of treatment approaches and the availability of treatment recommendations or guidelines, no consensus on the most effective pharmacological therapy of low back pain (LBP) has been reached yet. Therefore, additional clinical evidence, particularly if built upon a rigorous clinical trial design, an evidence-based medication choice, and broader inclusion criteria better acknowledging the heterogeneity and

show abstract

“…Numerous clinical studies support the use of tramadol/dexketoprofen as a safe and effective analgesic [13,[20][21][22]. In a single-center observational study, tramadol/dexketoprofen 75/25 mg was compared head-tohead to diclofenac/thiocolchicoside 75/4 mg for moderate to severe acute LBP [23]. Tramadol/dexketoprofen provided significantly greater and longer-duration analgesia at day three (93.2% vs. 73.7%) and day seven and had more responders at all time points in the study.…”

Section: Assumption Challenge Commentsmentioning

confidence: 99%

“…Tramadol/dexketoprofen provided significantly greater and longer-duration analgesia at day three (93.2% vs. 73.7%) and day seven and had more responders at all time points in the study. Reductions in neuropathic pain as measured on the Douleur Neuropathique 4 (DN4) survey were significantly greater with tramadol/dexketoprofen as well (-62.7 vs. -39.7, p<0.0001) [ 23 ].…”

Section: Reviewmentioning

confidence: 99%

Delivery of Multimodal Analgesia to Effectively Treat Acute Pain: A Review From Roma Pain Days

Hanna¹,

Matamala²,

Perrot³

et al. 2022

Cureus

View full text Add to dashboard Cite

It is crucial that acute pain be promptly and adequately treated in order to prevent it from transitioning to chronic pain, a devastating and sometimes permanent condition that is challenging to treat and associated with disability, reduced quality of life, and depression. Guidelines for the treatment of acute low-back pain (LBP) are predicated on assumptions that all acute LBP is benign, temporary, and traditionally treated with a "wait and see" approach. LBP is far from a monolithic condition: etiology, the presence of underlying conditions, mental health status, social situation, patient's age and occupation, and comorbidities all present different risk factors for chronic LBP that should be considered in treating acute LBP or other forms of acute pain. A multimodal approach to acute pain has been shown to be safe and effective. In particular, the combination product of oral dexketoprofen and tramadol has been shown effective in controlling acute pain, which spares the use of opioids and is well tolerated. Chronic pain must be viewed as a global health crisis, and the timely and adequate control of acute painful conditions is a good strategy to reduce its prevalence. Experts at Roma Pain Days discussed this important topic which is the foundation of this review.

show abstract

Efficacy and tolerability of orally administered tramadol/dexketoprofen fixed-dose combination compared to diclofenac/thiocolchicoside in acute low back pain: experience from an Italian, single-centre, observational study

Cited by 12 publications

References 31 publications

What Is New in the Clinical Management of Low Back Pain: A Narrative Review

What Is New in the Clinical Management of Low Back Pain: A Narrative Review

Delivery of Multimodal Analgesia to Effectively Treat Acute Pain: A Review From Roma Pain Days

Contact Info

Product

Resources

About